Optima TB: A tool to help optimally allocate tuberculosis spending
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Optima TB : A tool to help optimally allocate tuberculosis spending. / Goscé, Lara; Abou Jaoude, Gerard J.; Kedziora, David J.; Benedikt, Clemens; Hussain, Azfar; Jarvis, Sarah; Skrahina, Alena; Klimuk, Dzmitry; Hurevich, Henadz; Zhao, Feng; Fraser-Hurt, Nicole; Cheikh, Nejma; Gorgens, Marelize; Wilson, David J.; Abeysuriya, Romesh; Martin-Hughes, Rowan; Kelly, Sherrie L.; Roberts, Anna; Stuart, Robyn M.; Palmer, Tom; Panovska-Griffiths, Jasmina; Kerr, Cliff C.; Wilson, David P.; Haghparast-Bidgoli, Hassan; Skordis, Jolene; Abubakar, Ibrahim.
In: PLOS Computational Biology, Vol. 17, No. 9, e1009255, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Optima TB
T2 - A tool to help optimally allocate tuberculosis spending
AU - Goscé, Lara
AU - Abou Jaoude, Gerard J.
AU - Kedziora, David J.
AU - Benedikt, Clemens
AU - Hussain, Azfar
AU - Jarvis, Sarah
AU - Skrahina, Alena
AU - Klimuk, Dzmitry
AU - Hurevich, Henadz
AU - Zhao, Feng
AU - Fraser-Hurt, Nicole
AU - Cheikh, Nejma
AU - Gorgens, Marelize
AU - Wilson, David J.
AU - Abeysuriya, Romesh
AU - Martin-Hughes, Rowan
AU - Kelly, Sherrie L.
AU - Roberts, Anna
AU - Stuart, Robyn M.
AU - Palmer, Tom
AU - Panovska-Griffiths, Jasmina
AU - Kerr, Cliff C.
AU - Wilson, David P.
AU - Haghparast-Bidgoli, Hassan
AU - Skordis, Jolene
AU - Abubakar, Ibrahim
N1 - Publisher Copyright: © 2021 Goscé et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2021
Y1 - 2021
N2 - Approximately 85% of tuberculosis (TB) related deaths occur in low- and middle-income countries where health resources are scarce. Effective priority setting is required to maximise the impact of limited budgets. The Optima TB tool has been developed to support analytical capacity and inform evidence-based priority setting processes for TB health benefits package design. This paper outlines the Optima TB framework and how it was applied in Belarus, an upper-middle income country in Eastern Europe with a relatively high burden of TB. Optima TB is a population-based disease transmission model, with programmatic cost functions and an optimisation algorithm. Modelled populations include age-differentiated general populations and higher-risk populations such as people living with HIV. Populations and prospective interventions are defined in consultation with local stakeholders. In partnership with the latter, demographic, epidemiological, programmatic, as well as cost and spending data for these populations and interventions are then collated. An optimisation analysis of TB spending was conducted in Belarus, using program objectives and constraints defined in collaboration with local stakeholders, which included experts, decision makers, funders and organisations involved in service delivery, support and technical assistance. These analyses show that it is possible to improve health impact by redistributing current TB spending in Belarus. Specifically, shifting funding from inpatient- to outpatient-focused care models, and from mass screening to active case finding strategies, could reduce TB prevalence and mortality by up to 45% and 50%, respectively, by 2035. In addition, an optimised allocation of TB spending could lead to a reduction in drug-resistant TB infections by 40% over this period. This would support progress towards national TB targets without additional financial resources. The case study in Belarus demonstrates how reallocations of spending across existing and new interventions could have a substantial impact on TB outcomes. This highlights the potential for Optima TB and similar modelling tools to support evidence-based priority setting.
AB - Approximately 85% of tuberculosis (TB) related deaths occur in low- and middle-income countries where health resources are scarce. Effective priority setting is required to maximise the impact of limited budgets. The Optima TB tool has been developed to support analytical capacity and inform evidence-based priority setting processes for TB health benefits package design. This paper outlines the Optima TB framework and how it was applied in Belarus, an upper-middle income country in Eastern Europe with a relatively high burden of TB. Optima TB is a population-based disease transmission model, with programmatic cost functions and an optimisation algorithm. Modelled populations include age-differentiated general populations and higher-risk populations such as people living with HIV. Populations and prospective interventions are defined in consultation with local stakeholders. In partnership with the latter, demographic, epidemiological, programmatic, as well as cost and spending data for these populations and interventions are then collated. An optimisation analysis of TB spending was conducted in Belarus, using program objectives and constraints defined in collaboration with local stakeholders, which included experts, decision makers, funders and organisations involved in service delivery, support and technical assistance. These analyses show that it is possible to improve health impact by redistributing current TB spending in Belarus. Specifically, shifting funding from inpatient- to outpatient-focused care models, and from mass screening to active case finding strategies, could reduce TB prevalence and mortality by up to 45% and 50%, respectively, by 2035. In addition, an optimised allocation of TB spending could lead to a reduction in drug-resistant TB infections by 40% over this period. This would support progress towards national TB targets without additional financial resources. The case study in Belarus demonstrates how reallocations of spending across existing and new interventions could have a substantial impact on TB outcomes. This highlights the potential for Optima TB and similar modelling tools to support evidence-based priority setting.
U2 - 10.1371/JOURNAL.PCBI.1009255
DO - 10.1371/JOURNAL.PCBI.1009255
M3 - Journal article
C2 - 34570767
AN - SCOPUS:85118097024
VL - 17
JO - P L o S Computational Biology (Online)
JF - P L o S Computational Biology (Online)
SN - 1553-734X
IS - 9
M1 - e1009255
ER -
ID: 306896063